Search

everythinglearnresearchcommunity

for

Search:↓

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

Phototherapy effectively treats certain alopecia areata types, especially if started early.

Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Type B Insulin Resistance Syndrome is rare, linked to lupus, and hard to treat due to severe insulin resistance.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

Baricitinib may effectively treat oral lichen planus.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Late dumping syndrome after fundoplication can be diagnosed with an oral glucose tolerance test and managed with diet changes.

Treating chronic hand eczema costs about the same in statutory and occupational health insurances in Germany, but work-related cases may lead to higher indirect costs due to longer work absences.

Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.

The committee decided not to approve the drug due to low effectiveness and high risks.

Finasteride reduces Hidradenitis Suppurativa flare-ups in children and teens, but long-term safety is unknown.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Hair growth is influenced by various body and external factors, and neighboring hairs communicate to synchronize regeneration.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Skin stem cells are maintained by signals from nearby cells and vary in their ability to renew and mature.

Gilles de la Tourette syndrome is treatable, with behavioral therapy as a recommended first option and other treatments available for more severe cases.

Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.

Platelet-rich plasma shows potential for hair loss and skin rejuvenation but needs more research for widespread use.

Lupus treatment requires a combination of drugs and therapies, with research needed for new options.

Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.

New treatments for hair loss show promise, but more development is needed, especially for tough cases.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Operative hysteroscopy is still the main treatment for Asherman syndrome, but more research is needed on post-surgery methods.

New treatments for vitiligo show promise but still face challenges, especially for hands and feet.

Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.

Control inflammation and prevent further hair loss in folliculitis decalvans using medications and therapies.